% | $
Quotes you view appear here for quick access.

Celldex Therapeutics, Inc. Message Board

  • kokohead1 kokohead1 Nov 24, 2013 3:03 PM Flag


    OK you smart biotech guys and gals, is this better than expected, on par, or worse?

    Celldex Therapeutics' Rindopepimut Demonstrates Promising Clinical Activity in Patients with EGFRvIII-positive Recurrent Glioblastoma at SNO

    HAMPTON, N.J., Nov 24, 2013 (Menafn - GLOBE NEWSWIRE via COMTEX) --Strong interim survival trend (12.0 vs 7.9 months) emerging in ongoing bevacizumab naive randomized cohort; 5.6 month median OS (48% 6 months) in bevacizumab refractory single-arm cohort; robust anti-tumor immune responses were generated among heavily pre-treated patients with recurrent tumors and these responses correlate with improved outcome

    Rindopepimut demonstrates ability to significantly shrink recurrent and refractory glioblastomas

    Long-term survival update also provided for three Phase 2 frontline studies; EGFRvIII patients continue to exceed expectations with 14% 5-year survival vs 0% historical control

    Celldex Therapeutics, Inc. CLDX today reported interim data from its ongoing, exploratory Phase 2 ReACT study of rindopepimut in recurrent glioblastoma. Rindopepimut is an immunotherapeutic vaccine that targets the tumor specific oncogene EGFRvIII(v3). Patients with EGFRvIII-positive glioblastoma typically have a worse prognosis than the overall glioblastoma population, including poor long term survival. The ReACT results demonstrate promising signs of clinical activity in advanced patient populations, including patients both nave and refractory to bevacizumab (Avastin). An update on long-term survival for the three completed Phase 2 frontline studies in EGFRvIII-positive glioblastoma was also presented and results continue to exceed outcomes seen in contemporary controls. A webcast/conference call will be held at 8:30 am ET on Monday, November 25, to discuss the results (details provided below).

    The data were presented in an oral session by David A. Reardon, M.D., Clinical Director, Center for Neuro-Oncology, Dana-Farber Cancer Center and Associate Professor of

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
11.74-0.22(-1.84%)Oct 8 4:00 PMEDT